BGB-DXP593

DB16357InvestigationalProtein Based Therapies

BGB-DXP593 is a SARS-CoV-2 neutralizing antibody. It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants...

Mechanism: Pharmacologically active on Spike glycoprotein
Curator reviewed
Code names: BGB-DXP593

Resolves to

Targets

P0DTC2S

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with BGB-DXP593, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account